Nan Shan Life Insurance’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$86.2M Buy
3,070,309
+1,301,657
+74% +$34.7M 3.12% 9
2025
Q4
$44M Hold
1,768,652
1.35% 22
2025
Q3
$45.1M Hold
1,768,652
0.96% 30
2025
Q2
$42.9M Hold
1,768,652
0.95% 32
2025
Q1
$44.8M Hold
1,768,652
1.06% 24
2024
Q4
$46.9M Hold
1,768,652
1.13% 29
2024
Q3
$51.2M Buy
1,768,652
+849,971
+93% +$24.8M 1.21% 24
2024
Q2
$25.7M Buy
+918,681
New +$25.3M 0.61% 60

Other funds holding PFE

Nan Shan Life Insurance's PFE Position: Q1 2026 in Review

Nan Shan Life Insurance increased its Pfizer (PFE) stake by 74% in Q1 2026, buying an estimated $34.7M and bringing the position to 3,070,309 shares worth $86.2M. The position accounts for 3.12% of the portfolio, ranked #9.

Nan Shan Life Insurance first reported a position in PFE in Q2 2024 and has held it in 8 quarters since. 2,934 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • Nan Shan Life Insurance held 3,070,309 shares of Pfizer worth $86.2M as of Q1 2026.
  • Nan Shan Life Insurance bought 1,301,657 Pfizer shares in Q1 2026, an estimated $34.7M.
  • Pfizer made up 3.12% of Nan Shan Life Insurance's portfolio in Q1 2026, its #9 holding.
  • Nan Shan Life Insurance first reported a position in Pfizer in Q2 2024 and has held it in 8 quarters since.
  • 2,934 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on Nan Shan Life Insurance's 13F filing for Q1 2026, filed 14 May 2026.